Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
Conditions
- Metastatic Breast Cancer
- Advanced Breast Cancer
- Luminal Breast Cancer
- HER2-negative Breast Cancer
- ER-positive Breast Cancer
Interventions
- DRUG: Fulvestrant Injectable Product
- DRUG: Letrozole 2.5mg
- DRUG: Palbociclib 125mg
Sponsor
MedSIR
Collaborators